A Prospective, Randomized, Multiple-Dose, Multi-Center, Comparative, Parallel group Clinical Study to Evaluate the Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Subcutaneous Injection of Adalimumab (Test Product, Hetero) and Reference Medicinal Product (Reference product, AbbVie) Concomitantly Administered with Methotrexate in Patients with Rheumatoid Arthritis

Trial Profile

A Prospective, Randomized, Multiple-Dose, Multi-Center, Comparative, Parallel group Clinical Study to Evaluate the Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Subcutaneous Injection of Adalimumab (Test Product, Hetero) and Reference Medicinal Product (Reference product, AbbVie) Concomitantly Administered with Methotrexate in Patients with Rheumatoid Arthritis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Hetero Drugs
  • Most Recent Events

    • 18 Jul 2016 According to the pipeline section located at the URL - http://heteroworld.com/pages/business-Biosimilars/ , multiple phase III trials are ongoing. I have created only one profile since there is no information about the individual trials. Please split the trial as and when more information becomes available regarding these trials.
    • 18 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top